« Return to News | R&D Trends

Exonhit, Pfizer collaborate in Alzheimer’s research

Tuesday, October 11, 2011 02:26 PM

Exonhit has entered into a research agreement with Pfizer for the identification of new Alzheimer's disease biomarkers using Exonhit's Genome-Wide SpliceArray (GWSA) platform.

As part of the agreement, the two companies will jointly conduct a pilot study using Exonhit's GWSA platform to gain insight on AD molecular markers associated with clinical parameters. More specifically, the purpose of the research work is to seek to identify progression and other biomarkers that could segregate healthy elderly controls, patients with mild cognitive impairment (MCI) and patients with AD. Test samples for the study will be provided by Pfizer from a number of subjects in each of these three groups over a period of time.

Dr. Aidan Power, vice president and head of pharma therapeutics precision medicine at Pfizer, said: "Pfizer is committed to making a number of investments to evaluate technology platforms with the potential to identify new biomarkers of Alzheimer's disease. Our collaboration with ExonHit is one such example of this commitment. The discovery and validation of new AD biomarkers is important for Pfizer's effort to bring forward new treatment options for Alzheimer's patients as well as for the development of improved diagnostics."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.